Ampio Pharmaceuticals Starts Final Study for Osteoarthritis Treatment

Ampio Pharmaceuticals Starts Final Study for Osteoarthritis Treatment.

Jan 16, 2014 at 10:08AM

Ampio Pharmaceuticals (NYSEMKT:AMPE) thinks it has a new way to combat joint pain caused by osteoarthritis, and the growing Colorado biotech company is spending millions so it can hit the ground running if it gets FDA approval for its treatment.

Greenwood Village-based Ampio announced Monday that it is beginning a 500-patient Phase III pivotal clinical trial for Ampion, an anti-inflammatory molecule derived from human blood. Because it occurs naturally in the body, the molecule is expected to have few side effects, Ampio's chief regulatory officer Vaughan Clift said in a recent interview.

Ampio's new study will include patients between the ages of 35 and 85 who have knee pain caused by osteoarthritis. Study volunteers will be injected in the knee with a 4 milliliter dose of the molecule or a placebo, and their condition will be monitored for 20 weeks.

Clift said prior studies have already shown that Ampio's drug reduces osteoarthritis pain as well as drugs such as Vicodin or oxycodone but without the side effects and risk of addiction. It also provides relief for patients who have progressed through the typical osteoarthritis treatment regimen. That includes over-the-counter and prescription non-steroidal anti-inflammatory drugs in the early stages of the disease, followed by COX-2 inhibitors such as celecoxib (Celebrex) and then regular injections of hyaluronic acid, which replaces joint fluid and helps lubricate the joint.

If the condition worsens, the final treatment is surgery to replace the joint.

Ampio believes that its medication is better than COX-2 inhibitors and hyaluronic acid for managing the pain and says it has data showing it can treat severe cases that previously were untreatable by pharmaceuticals.

"We've had an effect on a population of patients for which there is no therapy, the patients in the most severe stages of the disease," Clift said.

There are about 27 million people with osteoarthritis, according to a National Institutes of Health report. That number is expected to grow as baby boomers age. The increase in obesity rates also could make the number climb, as carrying extra weight accelerates the wear on joints, Clift said.

If Ampion proves successful treating the condition when it affects the knee, Ampio will then try using it to treat pain in other joints and other illnesses.

"The applications of this drug are much, much bigger than just osteoarthritis of the knee," Clift said. "This is just our place to begin."

As of now, the market for osteoarthritis drugs is about $3.1 billion, and it is dominated by COX-2 inhibitors, according to Ampio.

Ampio expects to have results from the new trial in the third quarter of 2014. If all goes according to plan, Ampio could be selling the drug by mid 2015.

In the meantime, the company is already taking steps to be ready to produce and market the medication. On Friday, it started work on a new $7 million facility south of Denver. The building will include a research and development lab, a manufacturing setup able to produce Ampion at commercial scale, and room to consolidate business operations under a single roof.

Ampio, which was founded in 2010 and went public the next year, currently employs 18 people and has a market cap of $369 million. CEO Mike Macaluso said it plans to scale up "dramatically," and it could double its headcount. The new facility will give it the ability to manufacture 10 million doses of Ampion per year.

On the financial front, Ampio is trying to raise $100 million through a shelf offering, according to a prospectus filed with the SEC. In its last quarterly report, Ampio said it had $32 million in cash. It has yet to generate significant revenue.

How Ampio will sell the drug remains to be determined. Macaluso said the company is looking at a number of options, including selling it to a larger company or partnering with someone in a commercialization deal. It also could develop an in-house sales force or contract with a firm that would provide a sales team.

While the company expects Ampion to be a winner, it isn't the only product it is working on. Also in the pipeline, in Phase II testing, is a treatment for diabetic macular edema and diabetic retinopathy, conditions that can lead to blindness.

Ampio also has been busy on the corporate restructuring side. Late last year, it announced plans to spin off a new company focused on developing a treatment for premature ejaculation. The company, named Vyrix Pharmaceuticals, is expected to have an initial public offering sometime this year.

The Motley Fool's Top Stock for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

This article originally appeared on Xconomy, along with:

Michael Davidson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers